Forecast

The analysts' average price target is +10,30€ (+4.191,67%). The median is +12,88€ (+5.266,67%).

Buy	5
Hold	0
Sell	0

News Go to news feed

Skye Bioscience faces delisting after violating Nasdaq equity rule

Skye Bioscience received a notice from Nasdaq that it does not meet listing rule 5550(b)(1) because shareholders’ equity as of June 30, 2026 was −$497,307, below the required minimum of $2.5 million. The stock remains tradable on the Nasdaq Capital Market for now; the company has until October 2, 2026 to submit a plan to regain compliance, and if accepted Nasdaq can extend the deadline to February 14, 2027. According to the notice, Skye Bioscience is evaluating various measures to restore compliance and demonstrate the required minimum equity. » More on de.investing.com
Skye Bioscience lowers exercise prices for employee options and appoints John P. Sharp as CFO

The board of directors of Skye Bioscience approved resetting the exercise price for all employee options issued before December 31, 2025 to $0.6150 per share; the change affects options on 2,420,978 common shares. Beneficiaries include CEO Punit Dhillon (1,103,959 options) and COO Tuan Diep (396,295 options); all other terms remain unchanged. In addition, John P. Sharp was appointed chief financial officer effective March 31, 2026; his CFO services will be paid under a Master Services Agreement with a monthly flat fee of $25,600 for up to 64 working hours, and there are no reportable transactions or familial relationships. » More on de.investing.com
Skye Bioscience begins dosing in part C of phase-2a expansion study of Nimacimab

Skye Bioscience treated the first patient in part C of an expansion study of Nimacimab and is testing intravenous weekly doses of 400 mg and 600 mg over 15 weeks, followed by a 12-week follow-up. Each cohort includes eight participants, randomized 3:1 versus placebo, with enrollment in the 600 mg group contingent on a positive safety review after the 400 mg period. The goal is to collect preliminary safety and pharmacokinetic data to inform a dosing decision for possible combination therapies with incretins; topline results are expected in Q4 2026. The company emphasizes that the IV doses are intended to achieve higher peripheral tissue exposure; the stock is trading closer to its 52-week low, while the balance sheet shows more cash than short-term liabilities according to the data. » More on de.investing.com

Financials

In the last quarter, SKYE BIOSCIENCE DL -,001 Aktie had revenue of 0.00€ and net profit of −9.45m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−9.45m	36,79%
EBITDA	−9.45m	36,14%

Fundamentals

Metric	Value
Market capitalization	+7.35m€
Number of shares	4.39m
52-week high/low	+34,27€ - +1,58€
Dividends	No
Beta	2,99
P/E ratio	−0,19
PEG ratio	+0,01
P/B ratio	−19,45
P/S ratio	0,00

Company profile

Skye Bioscience, Inc. ist ein biopharmazeutisches Unternehmen, das Moleküle auf Cannabinoidbasis für die Behandlung von Infektionskrankheiten entdeckt, entwickelt und vermarktet. Der führende Produktkandidat des Unternehmens ist SBI-100, der sich in Phase-I-Studien zur Behandlung von Glaukom und Bluthochdruck im Auge befindet. Außerdem entwickelt es SBI-200, das sich in präklinischen Studien zur Behandlung und Kontrolle verschiedener Augenkrankheiten befindet, darunter Uveitis, Syndrom des trockenen Auges, Makuladegeneration und diabetische Retinopathie. Das Unternehmen war früher als Emerald Bioscience, Inc. bekannt und änderte im Januar 2021 seinen Namen in Skye Bioscience, Inc. Skye Bioscience, Inc. wurde im Jahr 2012 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.